Efficacy News and Research

RSS
Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Genzyme granted Priority Review for Cerdelga investigational oral therapy for Gaucher disease

Genzyme granted Priority Review for Cerdelga investigational oral therapy for Gaucher disease

Baxter seeks FDA approval of OBI-1 for adults with acquired hemophilia A

Baxter seeks FDA approval of OBI-1 for adults with acquired hemophilia A

Avanir Pharmaceuticals' AVP-923 phase II trial fails to meet primary efficacy endpoint

Avanir Pharmaceuticals' AVP-923 phase II trial fails to meet primary efficacy endpoint

Pemetrexed, paclitaxel regimens equally effective in NSCLC

Pemetrexed, paclitaxel regimens equally effective in NSCLC

Biosimulation and epilepsy treatments: an interview with Dr. Serge Bischoff, CEO of Rhenovia and RHENEPI program director

Biosimulation and epilepsy treatments: an interview with Dr. Serge Bischoff, CEO of Rhenovia and RHENEPI program director

FoundationOne Heme identifies clinically actionable genomic alterations in multiple myeloma cases

FoundationOne Heme identifies clinically actionable genomic alterations in multiple myeloma cases

Epilepsy experts discuss on new NTI definition, bioequivalence guidelines at AES annual meeting

Epilepsy experts discuss on new NTI definition, bioequivalence guidelines at AES annual meeting

Alnylam presents new pre-clinical data with ALN-AT3 for treatment of hemophilia and RBD

Alnylam presents new pre-clinical data with ALN-AT3 for treatment of hemophilia and RBD

RTMS safe and effective for hallucination in schizophrenia spectrum disorders

RTMS safe and effective for hallucination in schizophrenia spectrum disorders

Study offers new insight into benefits of vitamin D in people with multiple sclerosis

Study offers new insight into benefits of vitamin D in people with multiple sclerosis

Acetylon Pharmaceuticals presents positive interim data from two ricolinostat clinical trials at ASH 2013

Acetylon Pharmaceuticals presents positive interim data from two ricolinostat clinical trials at ASH 2013

FDA advisory committee backs Takeda's vedolizumab for treatment of ulcerative colitis, Crohn's disease

FDA advisory committee backs Takeda's vedolizumab for treatment of ulcerative colitis, Crohn's disease

Adocia gets development and commercialization rights in nanotechnology for drug delivery

Adocia gets development and commercialization rights in nanotechnology for drug delivery

Studies confirm superiority of Tasigna to Glivec at achieving molecular response in Ph+ CML patients

Studies confirm superiority of Tasigna to Glivec at achieving molecular response in Ph+ CML patients

Ligand announces data from preclinical studies on small-molecule oral G-CSF receptor agonist

Ligand announces data from preclinical studies on small-molecule oral G-CSF receptor agonist

New form of gene therapy shows promising outcomes for "bubble boy" disease

New form of gene therapy shows promising outcomes for "bubble boy" disease

Genetically engineered cell therapies demonstrate early efficacy, safety in patients with blood disorders

Genetically engineered cell therapies demonstrate early efficacy, safety in patients with blood disorders

MRI-guided SLA surgery proves safe and shows adequate efficacy for seizure control

MRI-guided SLA surgery proves safe and shows adequate efficacy for seizure control

Study demonstrates safety and efficacy of NeuroPace RNS System in adults with intractable seizures

Study demonstrates safety and efficacy of NeuroPace RNS System in adults with intractable seizures

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.